US Edition
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
A group from the National Center for Oncological Research (CNIO) has identified a new mechanism that could help explain how a genetic variant in the gene that encodes chemotripsinogen 2, CTRB2, increases the risk of developing pancreatic cancer.
ASU to help target how cancer evades treatment - Phoenix Bioscience Core
Facebook Twitter LinkedIn Email Print Up to $142M in funding announced for research group that includes MIT and Stanford As part of an Advanced Research Projects Agency for Health program, an ASU team including Carlo Maley (left) will work to advance new computer tools that can better predict how cancer grows and changes. These tools will help doctors choose better treatments faster — before the cancer becomes harder to treat. Photo by Quinton K…
Char-Koosta News
Macau BusinessContinuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
